BACKGROUND

Effective January 1, 2016, methylphenidate ER manufactured by labeler 00591 will become the only preferred methylphenidate on the Universal Preferred Drug List. All other generics for methylphenidate ER will be non-preferred and should deny at point of sale.

MAILING

All prescription claims (FFS and CCOs) for methylphenidate products filled in 2015 were extracted. A total of 710 pharmacies were identified as having filled methylphenidate prescriptions. Since most of the pharmacies with the lowest number of prescriptions had filled prescriptions for multiple beneficiaries, the educational letter was mailed to all pharmacies having filled methylphenidate prescriptions in 2015. The attached letter was mailed to these pharmacies.
December 1, 2015

IMPORTANT INFORMATION ABOUT JANUARY 1, 2016 MEDICAID UNIVERSAL PREFERRED DRUG LIST:

Authorized generic, methylphenidate ER, by labeler 00591, is the only preferred methylphenidate ER agent on UPDL

Dear Pharmacy Provider:

Background: Your pharmacy was identified as having dispensed generic Concerta for Medicaid beneficiaries during the last few months. Be advised that the MS Division of Medicaid (DOM) will designate some generic products, manufactured by a specific manufacturer, as preferred drugs while other generics of the same entity will be designated as non-preferred drugs. The purpose of this letter is to notify providers in order to stock the preferred authorized generic prior to January 1, 2016.

What are authorized generics? The term Authorized Generic™ refers to prescription drugs that are produced by brand companies under a New Drug Application (NDA) and marketed as generics under private label. The Authorized Generic™ is sold and distributed as a generic product but has the identical size, shape, color, taste, smell, mouth feel, and active ingredients as the brand product.

Unlike other generics, the Authorized Generic™ has the identical inactive ingredients as the brand. Authorized Generic™ provide patients, payers and taxpayers the highest brand quality at lower generic prices. Both authorized generics and generic products are highly regulated and undergo a rigorous approval process resulting in a safe and effective treatment methodology. Because authorized generics offer the Division of Medicaid a better net cost than non-authorized generic versions of a drug, Medicaid may designate authorized generics manufactured by a specific manufacturer as preferred while other generics of the same entity will be designated as non-preferred drugs.

Impact on pharmacies: Effective January 1, 2016, methylphenidate ER manufactured by labeler 00591 becomes the only preferred methylphenidate on the Universal Preferred Drug List. All other generics for methylphenidate ER will be non-preferred and deny at point of sale. DOM is alerting providers in order to stock this product, prior to January 1, 2016, and avoid denials at point of sale.

The UPDL section for long-acting stimulants is shown with these changes in preferred drug status highlighted. The full UPDL can be found at:

http://www.medicaid.ms.gov/providers/pharmacy/preferred-drug-list/

Sincerely

Shannon P. Hardwick, R.Ph.
Clinical Director
MS-DUR

Judith P. Clark, R.Ph., B.S. Pharmacy
Director, Office of Pharmacy
Division of Medicaid

http://www.pharmacy.olemiss.edu/cpmm/msdur.html